SynthesisBMC infectious diseases2026
Immunogenicity and safety of novel oral polio vaccine type 2 (nOPV2) in pediatric populations: a systematic review and Bayesian meta-analysis.
Synthesis in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFollowing the 2016 global cessation of oral poliovirus vaccine type 2, outbreaks of circulating vaccine-derived poliovirus type 2 have posed significant public health challenges. The novel oral poliovirus vaccine type 2 (nOPV2), developed for enhanced genetic stability, lacks comprehensive pediatric data.
objectiveTo systematically evaluate nOPV2 immunogenicity and safety in under-immunized pediatric populations through Bayesian meta-analysis.
methodsWe searched five databases from 2015 to 2025 for RCTs and observational studies of nOPV2 in children under 18 years from under-immunized populations. Bayesian single-arm meta-analyses were performed.
resultsFive studies (four RCTs, one cohort) with 10,421 children from Bangladesh, The Gambia, and the Dominican Republic were included. Pooled seroconversion rates ranged from 65.8% to 81.5%. Severe adverse events after nOPV2 vaccination yielded a pooled proportion of 0.01 (95% CI: 0.00-0.02), mild events occurred in 7.8%, and viral shedding was 64.7%.
conclusionsnOPV2 shows robust immunogenicity and excellent safety, supporting its role in outbreak control and global polio eradication. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.